Detalhe da pesquisa
1.
A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative Colitis.
Gastroenterology
; 160(1): 115-127.e30, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32763240
2.
SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial.
Clin Infect Dis
; 72(12): 2132-2140, 2021 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32255488
3.
A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents Recurrent Clostridium difficile Infection.
J Infect Dis
; 214(2): 173-81, 2016 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26908752
4.
Reply to Lagier et al.
J Infect Dis
; 215(1): 162-164, 2017 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28077592
5.
Vesicular stomatitis virus: an exciting new therapeutic oncolytic virus candidate for cancer or just another chapter from Field's Virology?
Cancer Cell
; 4(4): 241-3, 2003 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-14585348
6.
Dosing a synbiotic of human milk oligosaccharides and B. infantis leads to reversible engraftment in healthy adult microbiomes without antibiotics.
Cell Host Microbe
; 30(5): 712-725.e7, 2022 05 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35504279
7.
Selective targeting of antitumor immune responses with engineered live-attenuated Listeria monocytogenes.
Cancer Res
; 66(2): 1096-104, 2006 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16424046
8.
Listeria-based cancer vaccines that segregate immunogenicity from toxicity.
Proc Natl Acad Sci U S A
; 101(38): 13832-7, 2004 Sep 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-15365184